This approach assumes the creation of surfaces that possess a minimal adsorption of proteins and blood cells, since this phenomenon is considered as the very first step for further thrombotic response, blood clotting, and biochemical cascade reaction, which result in severe health problems for HD patients. Although the aim of biopassive surfaces is to minimize triggering immune response reactions, the effectiveness of this approach for long-term applications is still a major concern. Hence, a bioinactive surface is hardly suitable for biomedical implants, but is a good option for short-term or single-use applications such as hemodialysis.

4.2. Bioactive Surfaces

This approach utilizes the immobilization of bioactive compounds that minimize the immune response by interacting with key blood components or by releasing bioactive compounds. Nitric oxide (NO) is a gaseous free radical molecule that attenuates the interaction of platelets to the adsorbed fibrinogen, von Willebrand factor, and other blood proteins, resulting in reduced platelet activation [30]^[13]. Moreover, this approach is based on the ability of the endothelial lining of blood vessel cells to synthesize and exhaust NO from L-arginine at an estimated flux of 0.5 to 4.0 × 10⁻¹⁰ mol/cm²/min [31]^[14]. NO producing materials depend on the NO generation triggering type including physiologically, enzymatic, chemical, and thermal activated [32,33,34,35]^{[15][16][17][18]}. Ex vivo experiments have demonstrated a significant reduction in the thrombus formation in human blood and the inhibition of platelet aggregation in platelet rich plasma [36]^[19]. Earlier in vivo experiments in developing NO releasing materials allowed for a reduction in the thrombus area up to six times in a 7 h rabbit ECC model [37]^[20]. Recent work with NO releasing materials indicated the viability of this approach for ECC applications, wherein the maintenance of 90% of the baseline platelet count was achieved in a 4 h rabbit model using polyvinylchloride (PVC) tubing [38]^[21].

5. Heparin-Immobilized Dialysis Membranes

A hollow-fiber oxygenator membrane was covalently coated with nitrous acid degraded heparin using aqueous free radical activation and oxygenation and the coupling of a polyethyleneimine spacer [52]^[22]. This coating technology allowed for a heparin surface density of 3.5 μg/cm² to be achieved. Protein adsorption was performed within 6 h. The binding mechanisms of the proteins were demonstrated to be changed for a heparin-coated surface that resulted in less protein adsorption, which was observed starting from 10 min of the experiment. However, complement system initiator proteins were detected to bind more to the heparinized membrane. The Klotho (KL) gene was cross-linked with heparin to the acellular small intestinal submucosa (SIS) [53]^[23]. In vivo experiments demonstrated enhanced adhesion of the endothelial cells on the SIS membrane, resulting in increased patency rate, endothelialization, and smooth muscle regeneration, which indicates improved hemocompatibility. This approach of promoting endothelial cell growth on the implant surface demonstrates promising results, though at the moment, it is hardly applicable for the biocompatibility of hollow fiber-based HD membrane modules. To simplify the membrane surface heparinization, a chitosan support layer was used [54]^[24]. Chitosan was directly added to the PES spinning solution, so further heparinization can be easily performed just by treating of hollow fibers with heparin solution. The autscholars proposed performing this procedure right before the HD session to minimize the immobilized heparin degradation. The resultant membranes were observed to possess a reduction in the thrombin–antithrombin complex, active complement component 3, and platelet factor 4 concentration, which indicates an improvement in hemocompatibility. Moreover, the above-mentioned modification with heparin increased the membrane flux (for pure water). Chitosan was also used for heparin immobilization on a thermo-responsive poly(N-isopropylacrylamide) (PNIPAM) polymer, that is, used for controlled drug release and tissue engineering [56]^[25]. Up to 10 layers of alternating layers of chitosan and heparin were created. To enhance the resultant complex stability layers were covalently cross-linked using 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDC) and N-hydroxysuccinimide (NHS), which resulted in a reduced surface charge that is associated with the minimization of heparin and chitosan loss. Moreover, the cross-linked complex demonstrated better biocompatibility in terms of the growth of C3H10T1/2 cells after 24 h of cultivation. However, an uncross-linked chitosan/heparin complex was reported to be successfully used as an implant for 5 months for vascular regeneration [57]^[26].  The layer-by-layer self-assembly (LbL) technique was used to immobilize heparin with the oppositely charged dihydroxy-iron (DHI) on the bovine pericardial scaffold (BPS) surface [58]^[27]. This cycle was repeated up to 10 times to create a multi-layer structure with alternating charged layers. The resultant complex was not stable and was able to gradually release heparin, thus resulting in 30 days of anticoagulant activity in the in vitro tests. As was previously discussed, the presence of heparin in human blood is able to provoke undesired consequences such as HIT. Heparin dosage is always a critical point for HD sessions, thus additional research is necessary to develop this approach. Heparin was also used to improve the hemocompatibility and hydrophilicity of the extreme hydrophobic nature of poly(ε-caprolactone) (PCL) to create vascular graft implants [60]^[28]. Heparin-coated PCL nanofibrous scaffolds were prepared using gamma irradiation and N-(3-dimethylaminopropyl)-N′-ethyl carbodiimide hydrochloride/N-hydroxysuccinimide reaction chemistry on a preliminary 2-aminoethyl methacrylate (AEMA) hydrochloride grafted surface. The resultant modification reduced the fibrinogen adsorption to 4 μg/mm² (twice less compared with the unmodified PCL vascular graft).

Moreover, improvement in the recovery of blood vessel function was observed for implanted heparin-coated vascular grafts into 24-month-old Sprague Dawley rats due to promoting the proliferation of endothelial cells and preventing thrombosis. The examples of using heparin through different approaches of its immobilization on various surfaces and the resulting outcomes are listed in Table 2.

Table 2.

The effects of the different approaches of heparin immobilization.

No.	System	Preparation Method	Outcome in Hemocompatibility and Performance	Ref.
1	PTFE HD arteriovenous graft with attached heparin	Commercial product.	No benefit of using heparin. The number of cases of open or percutaneous thrombectomy was significantly higher for heparin-coated grafts as well as the number of any intervention performed to maintain graft patency. Kaplan–Meier survival curve also shows no positive effect of using heparin.	[61]
2	Low-molecular weight heparin injections		Heparin prevents blood coagulation.	[62]
3	Heparin injections		Heparin increases the activated clotting time (ACT) from 150 s to 300 s depending on dosage. Survival is improved by increased heparin administration independent of the ACT.	[63]
4	Heparin (fractioned and unfractioned) injections		When fractioned heparin was used, it resulted in increasing the density of lipoproteins that is associated with atherosclerotic cardiovascular disease. Unfractionated heparin reduces these effects.	[64]
5	Barium alginate microcapsules with conjugate heparin	Alginate microcapsules were incubated with avidin with further treatment with heparin solution.	Immobilized heparin reduces pericapsular fibrotic overgrowth (PFO) both in syngeneic and allogeneic rat transplantation models by ~65% and ~43%, respectively (in-vivo experiments).	[39]
6	Pullulan acetate (PA)/polyethylene glycol (PEG) membrane with conjugated heparin	Heparin was immobilized using PEG spacer and N-hydroxysuccinimide.	Improved resistance to platelet adhesion.	[65]
7	Alginate capsules covered with poly-l-lysine (PLL) heparin	Alginate capsules were covered with positively charged poly-L-lysine with further immobilization of heparin or acrylic acid.	Use of heparin resulted in the appearance of fibroblasts and macrophages on the capsules (in-vivo rat tissues). When heparin was replaced by poly-acrylic acid, this effect was not observed.	[40]
8	Low-molecular weight heparin injections		Use of heparin in a coagulation preventive dose caused heparin-induced thrombocytopenia (HIT) type 1 and 2	[66–78]
9	Polyurethane (PU) coated with chitosan/heparin layer-by-layer.	Heparin / chitosan was immobilized on PU surface using 1,6-diisocyanatohexane in the presence of dibutyltin dilaurate.	Increase in blood clotting and recalcification time in the in vitro experiments. Thromboresistance was 83.94 ± 8.12% − 86.22 ± 5.29% after 20–240 min. In vivo hemolysis ratio was less than 0.01%.	[49]
10	Covalently attached heparin to membrane for artificial lung use.	Commercial product.	Heparin reduces activated coagulation time (ACT) from approx. 250 s to 150 s compared to the non-heparinized membrane. Lung performance parameters remained approximately the same	[79]
11	Heparin coated circuit parts	Commercial product.	Reduction in the terminal complement complexes when using heparin. Improvement in biocompatibility.	[80]
12	PTFE coated with bovine serum albumin (BSA)/heparin multilayers	Heparin/BSA was immobilized using cross-link by glutaraldehyde or without it.	The BSA/heparin layer, cross-linked by glutaraldehyde, prevented fibrinogen adsorption and platelet adherence on the PTFE surface.	[51]
13	TiO2 surface coated with heparin	TiO2 surface was coated with conjugate of polydopamine (PDA) and poly(ethyleneimine) (PEI). Then heparin was attached to this conjugate using N-hydroxysuccinimide (NHS) and N-(3-dimethylaminopropyl)-N’-ethylcarbodiimide (EDC).	Increase of activated partial thromboplastin time (APTT) from 35 s (pristine TiO2) to 55–57 s for heparin-coated TiO2. Heparin-coated TiO2 also inhibited platelet adhesion.	[81]
14	Titan surface coated with laminin/heparin complex	Laminin/heparin complex was covalently immobilized onto poly-L-lysine (PLL) coated titan surface with help of 1-ethyl-3-dimethylaminopropyl carbodiimide (EDC), N-hydroxy-2,5-dioxopyrol-idine-3-sulfonicacid sodium salt (NHS) and 2-morpholinoethane sulfonic acid (MES).	The amount of immobilized heparin depends on the amount of used laminin. When high concentrations (more than 150 μg/mL) of laminin were used, it significantly increased the activated partial thromboplastin time (APTT) to more than 190 s while the uncoated Ti surface possessed an APTT of 30 s. A lower amount of laminin increased the APTT to 90–120 s.	[44]
15	PLA surface coated with heparin	Heparin was conjugated with chitosan coated polylactic acid (PLA) surface.	Chitosan/heparin complex prevented platelet adhesion and their activation in blood contact in the in vitro tests. At the same time, the L929 fibroblast adhesion test showed that the PLA surface adsorbed only 20% of cells, whereas the chitosan/heparin coating increased this value to 70%, which was greater than for the PLA coated with chitosan only (40% relative adsorption).	[43]
16	The extracorporeal circuit of low-flux cellulose dialyzers was rinsed with heparin solution	Commercial product.	75% of heparin-treated dialyzers showed a decrease in the vascular endothelial basic fibroblast growth factor VEGF165. It was more profound for patients with ischemic heart disease.	[82]
17	Fixation of heparin on biological tissue	Fresh porcine pericardia was used as biological tissue. For ionic immobilization, the tissue was treated with 2.1% protamine sulfate with further treatment with 0.625% glutaraldehyde or genipin. For covalent immobilization tissue was treated with 0.625% glutaraldehyde or genipin with further treatment with 2% water-soluble carbodiimide, 1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide hydrochloride.	Heparin increased the surface hydrophilicity and reduced fibrinogen and platelet adsorption. At the same time, covalently attached heparin resulted in a greater hydrophobic surface and increased the amount of adsorbed fibrinogen and platelets compared with ionically immobilized heparin.	[42]
18	Polyurethane (PU) films coated with chitosan/heparin	PU film was treated with plasma with further growing polyacrylamide. Then, films were treated with glutaraldehyde with the further addition of chitosan (CH) and heparin (Hep).	Both surfaces were shown to possess antibacterial properties with some improvement for PU-CH-Hep.	[83]
19	Glass and PVC surfaces coated with heparin	PVC surface was treated with radiofrequency SF6 plasma with further chemical vapor deposition from heparin/isopropanol and heparin/hexamethyldisiloxane solutions.	The coagulation time of blood was increased by about 20–60%.	[84]
20	Electrospun bilayered bioresorbable small-diameter vascular grafts (SDVG) based on blends of poly(L-lactic acid) (PLLA) and segmented polyurethane (PHD), coated with heparin	Electrospun fibers were treated with allyl glycidyl ether with further addition of poly(ethylene glycol) bis(amine). Then heparin was immobilized with help of 2-(4-Morpholino) ethanesulfonic acid (MES), 1-(3-Dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride and N-hydroxysulfosuccinimide sodium salt (sNHS).	Heparin-coated surface promoted a stable and functional endothelial cell layer.	[85]
21	Alkylated polyelectrolyte thin film surface with immobilized heparin	Heparin was chemically modified by end-point conjugation to biotin and immobilized onto membrane-mimetic thin films via biotin–streptavidin interactions.	Heparin promoted ATIII-mediated thrombin inactivation.	[86]
22	Polysulfone (PSf) membrane coated with heparin/polydopamine (PDA)/polyethyleneimine (PEI)	PSf membranes were treated with PDA/PEI mixture. Then membrane was incubated into heparin and 1-Ethyl-3-(aminopropyl)carbodiimide (EDC)/N-hydroxysucciimide (NHS) mixture solutions	Heparin-modified PSf membranes possessed high selectivity for LDL removal and a reduction in the rate of platelet adhesion.	[87]
23	Stainless steel with covalently attached heparin-liposomes complex.	Stainless steel surfaces were treated with plasma with further deposition of acrylic acid and heparin-liposomes.	Increase in blood coagulation time.	[88]
24	PVC tubing coated with heparin	Commercial product.	It was demonstrated that the immobilization of heparin altered the composition of surface-adsorbed proteins and promoted the AT-mediated inhibition of surface adsorbed FXIIa and FXIa, unlike free heparin in solution.	[89]
25	Polyacrylonitrile HD membrane coated with chitosan/heparin conjugate	Chitosan (CS)/heparin (HEP) polyelectrolyte complex (PEC) was covalently immobilized onto the surface of polyacrylonitrile (PAN) membrane with help of glutaraldehyde and 1-ethyl-3-(3-di-methylaminopropyl) carbodiimide (EDC).	Coated PEC reduced protein adsorption, platelet adhesion, and thrombus formation. Additionally, immobilized PEC could suppress the proliferation of Pseudomonas aeruginosa.	[90]
26	Graphene oxide with covered heparin, incorporated in polyetherimide membranes	Heparin was immobilized on the graphene oxide surface with the help of dopamine hydrochloride. Then, film and hollow fiber-based membranes with inclusions of modified graphene oxide were prepared.	Heparin reduced the platelet adhesion/activation (103 times), increased the blood clotting time (APPT 235 s), and lowered thrombin generation. Hemolysis ratio was less than 2%. Outstanding removal of uremic toxins after 4 h (Urea 77 ± 2.5%, creatinine 68 ± 2%, and lysozyme 44 ± 2%) and ~95% retention of human serum albumin was shown.	[91]
27	Heparin injections during HD		Skin necrosis due to the proposed acquired antithrombin III deficiency. Multiple erythematous, tender lesions developed over the abdomen.	[92]
28	HD procedure with heparin		Heparin-associated antiplatelet antibody (HAAb) positive patients experienced higher risk of thromboembolic and hemorrhagic complications (60% vs. 8.7% for control group) and higher related mortality (28.6% vs. 4.35% for control group).	[93]
29	Heparin-bonded polytetrafluorethylene HD arteriovenous graft (AVG)	Commercial product.	Rates of reintervention and thrombectomy were higher for the heparin-coated PTFE AVGs.	[94]
30	Heparin-coated polyacrylonitrile HD membrane	Heparin-coated polyacrylonitrile membrane (AN69ST) was compared with regional Citrate Anticoagulation.	Heparin-coated PAN membrane resulted in blood clotting in 39% of HD sessions, whereas no or 13% clotting occurred for citrate anticoagulation depending on citrate concentration.	[95]
31	Polyacrylonitrile (PAN) electrospun scaffold and heparin-poly(vinyl alcohol) (heparin-PVA) hydrogel coating HD membranes	Heparin was chemically attached to PVA with help of glutaraldehyde. Then, it was mixed with PAN and electrospun.	Heparin reduced membrane fouling with proteins and improved anticoagulation.	[96]
32	Immobilized heparin on PVDF membranes with microporous structures	First, polyacrylic acid was grafted on the PVDF surface. Then, heparin was covalently attached using (1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide hydrochloride.	Heparin reduced platelet adhesion	[97]
33	Dopamine-covered 316 L stainless steel surface coated with heparin/poly-L-lysine nanoparticles	Stainless steel was covered with dopamine with the further addition of heparin/poly-L-lysine nanoparticles.	Heparin prolonged the APTT and TT times, although a heparin density of more than 20 μg/cm2 was unsuitable for vascular cell proliferation and endothelium regeneration.	[48]
34	Polycarbonate film with immobilized heparin	Heparin was attached to the PCL surface via aminolysis modification.	Heparin increased the surface negative charge, resulting in increased protein adsorption.	[98]
35	GORE-TEX1 vascular grafts (PTFE) with immobilized heparin	Commercial product.	Heparin-coated PTFE grafts remained patent and had significantly greater thrombus-free luminal surface. The bioactivity of heparin was retained for a period of up to 12 weeks.	[99]
36	liquid crystalline hydroxypropyl cellulose ester film with immobilized heparin	Heparin was directly attached to cellulose surface using NaOH.	Heparin increased the activated partial thromboplastin time (APTT) and prothrombin time (PT) as well as the plasma re-calcification time (PRT) and reduced coagulation activation.	[100]
37	Alginate microbeads covered with polyallylamine (PAV)/macromolecular heparin conjugates	Heparin/PAV complex was attached to alginate microbeads using poly-L-lysine.	Heparin–PAV complex increased anticlot activity, lowered cytotoxicity, reduced elevated complement, leukocyte CD11b, and fibrotic overgrowth.	[50]
38	Hollow-fiber based PES HD membrane, modified with tannic acid (TA)/poly(2-ethyl-2-oxazoline) (PEtOx)/heparin	PES hollow fibers were covered with TA, then partially hydrolyzed PetOx was added with the further immobilization of heparin.	TA/PEtOx/Hep complex protected cardiomyocytes (H9C2) and vascular endothelial cells (HUVEC) from oxidative damage. Additionally, activated partial thromboplastin time was prolonged and complement activation was reduced.	[45]
39	Polyvinyl chloride (PVC) tubes and capillary membrane oxygenators with heparin-modified hollow fibers	Commercial product.	Immobilization of heparin resulted in reduced attachment of activated C3 and C5b-9 to the membrane surface in the invitro experiment and improved long-term hemocompatibility.	[101]
40	PVC surface coated with heparin and nitric oxide.	Heparin/copper nanoparticles and NO-generating substances were immobilized via tyrosinase (Tyr)-mediated reaction.	Heparin/copper nanoparticles/NO-generating generating complex demonstrated reduced inflammatory response and improved the adaptation of implants in vivo. Additionally, the complex promoted endothelialization and inhibited coagulation and platelet activation	[102]
41	PES HD membrane.	Heparin was added during HD.	In vitro, heparin reduced the rate of superoxide release from separated 12-myristate 13-acetate (PMA)-stimulated peripheral blood polymorphonuclear leukocytes (PMNLs). In vivo, the rate of superoxide release from PNMLs was significantly reduced for heparin use.	[103]
42	Cellulose membrane with covalently attached heparin	Visking@ dialysis tubes were modified with heparin (HE), dextran sulfate (DX), dermatan sulfate (DS), and endothelial cell surface heparan sulfate (ES-HS) using the photochemical heterobifunctional reagent 4-azido-lfluoro-2-nitrobenzene (AFNB).	Heparin-coated membrane showed 50% reduced platelet adhesion. ES-HS modified membranes demonstrated no platelet adhesion.	[104]
43	Polyetherimide (PEI) with attached heparin	Heparin was covalently attached to the PEI surface via the amide group reaction.	Heparin caused a significant reduction in the platelet adhesion as well as the reduction in cell growth and metabolic activity	[105]
44	Bio-based poly(lactic acid) (PLA) membrane with attached heparin	Heparin was immobilized to the PLA membrane surface via reaction with dopamine.	Suppressed platelet adhesion, prolonged plasma recalcification time, and decreased the hemolysis ratio.	[106]
45	Styrene-butadiene-styrene (SBS) copolymer-based membrane with immobilized poly-vinylpyridine/heparin	Heparin was attached to polymer surface using poly-vinylpyridine.	Reduced adsorption of albumin and fibrinogen.	[46]
46	Polyvinyl chloride (PVC) based sodium selective membrane electrode coated with chitosan/heparin	Heparin/chitosan was attached using carbonyldiimidazole (CDI).	Reduced platelet adhesion	[107]
47	Heparin grafted HD dialyzers based on polyaryethersulfone/polyamide, polysulfone, polyethersulfone, polyarylethersulfone, cellulose triacetate	Dialyzers from several manufacturers.	Increase in the success rate of the HD sessions for heparin-grafted dialyzers (68.5% versus 50.4% for the control group).	[108]
48	Gold covered SUS316L stainless steel (SS) sheet	Alternatively immobilized chondroitin 6-sulfate (ChS) and heparin (HEP) layers on gold-coated SS.	Increase in the blood clotting time	[109]
49	Titanium surface covered with chitosan (CS)/heparin (Hep)	Heparin was covalently immobilized on the alkali treated titanium surface with further immobilization of CS with electrostatic bonding.	Reduction in protein absorption, blood clot mass, and platelet adhesion. Additionally, antibacterial activity was observed.	[47]
50	Polyisobutylene-based thermoplastic elastomer (TPE) with immobilized heparin	Heparin was immobilized using 1-ethyl-3-(dimethyl-aminopropyl) carbodiimide hydrochloride (EDAC) and azidobenzoic acid/propine acid	Hindered accessibility of the heparin active site to antithrombin.	[110]
51	Hydrophobic polyethylene (PE) porous membrane covered with poly-dopamine/heparin	Heparin was covalently attached to the PE surface with dopamine.	Suppressed platelet adhesion and improved anticoagulation in vitro.	[111]
52	Polytetrafluoroethylene (PTFE) with a heparin-immobilized extracellular matrix (ECM) coating	Heparin was attached to the ECM coating.	Reduced endothelial cell (EC) growth and improved smooth muscle cell (SMC) proliferation, though platelet adhesion was observed at a low heparin surface density (4.89 ± 1.02 μg/cm2).	[112]
53	Heparin-coated dialyzer membrane modules	Commercial dialyzers.	73% of HD sessions ended up with Grade 3 and Grade 4 clotting. No significant benefit of using heparin over vitamin E was shown.	[2]

6. Conclusions

6. Conclusions

The development of antifouling and anti-clotting materials is of great importance for hemodialysis and biomedical applications. The current tendency in the development of biocompatible materials is to design a membrane with near-zero charge due to the immobilization of zwitterionic molecules or pseudo-zwitterionic complexes. Achieving a near-zero charge dialysis membrane will minimize any possible electrostatic interaction with human serum proteins or other molecules, whose adsorption can provoke further cascade reactions and related undesired consequences.

The possibilities of current chemistry allow us to synthesize tunable structures with the desired properties that are potentially capable of replacing heparin and providing ultimate hemocompatibility. At the same time, it is also possible to use heparin for the creation of complex conjugates that eliminate heparin drawbacks, although this approach seems to be less promising than the controlled synthesis of heparin-mimicking polymers.

Achieving a biopassive antifouling surface that possesses minimal adsorption of proteins and blood cells is urgently required, since this phenomenon is considered as the very first step for further thrombotic response, blood clotting, and biochemical cascade reaction, which result in severe health problems for HD patients. Though the aim of biopassive surfaces is to minimize triggering immune response reactions, the effectiveness of this approach for long-term applications is still a major concern. Hence, a bioinactive surface is hardly suitable for biomedical implants, but is a good option for short-term or single-use applications such as hemodialysis. On the other hand, a bioactive surface utilizes the immobilization of bioactive compounds that minimize the immune response by interacting with key blood components or by releasing bioactive compounds.

Furthermore, with the methods mentioned in our study, it is more suitable for modifying flat-sheet membranes. However, studies to date on the heparin or heparin-mimicking modification of hollow fibers are not sufficient or well-tested. Therefore, in future studies, much more attention should be paid to the surface modification of hollow fiber membranes.

A few studies have succeeded in the mimicking of heparin conformation, since the anticoagulant of heparin is not only derived from the chemical groups, but also because the specific conformation of heparin may also promote the binding of coagulant factors. Thus, with a further understanding of heparin, the ultimate goal should be to design advanced heparin-mimicking polymers with both mimicking groups and conformations. It is believed that this review will evoke more attention toward the design of heparinized and heparin-like/mimicking membranes and encourage future advancements of this emerging research field.

Author Contributions:  Conceptualization, A.A; formal analysis, D.K.; investigation, A.A. and A.S.; visualization, D.K.; supervision, A.A.; project administration, A.A.; funding acquisition, A.A. All authors have read and agreed to the published version of the manuscript.

Abbreviations

Funding:  Saskatchewan Research Health Foundation (SHRF).

Institutional Review Board Statement: Amira Abdelrasoul, the principal investigator of the project, obtained Research Ethics Approval and Operational Approval to conduct this research from the Saskatchewan Health Authority. She is responsible for the regulatory approvals that pertain to this project, and for ensuring the project was conducted according to the governing law. All participants in this study signed a written informed consent, approved by the University of Saskatchewan Biomedical Research Ethics Board (Bio-REB).

Acknowledgments: The authors acknowledge the funding support from the Saskatchewan Research Health Foundation (SHRF). The authors are also grateful to the University of Saskatchewan (U of S) for all of the facilities provided to conduct this research in collaboration with the Saskatchewan Transplant Program at St. Paul’s Hospital, Saskatoon.

Conflicts of Interest: The authors declare no conflicts of interest.

Abbreviations

 

Abbreviation	Meaning
HIT	Heparin-induced thrombocytopenia
PF4	Platelet factor 4
HD	Hemodialysis
C3	Complement component 3
HSA	Human serum albumin
FB	Fibrinogen
TRF	Transferrin
SH	Superhydrophobic
ZW	Zwitterionic
NO	Nitric oxide
ECC	Extracorporeal circuits
PVC	Polyvinyl chloride
KL	The Klotho Gene
SIS	Small intestinal submucosa
PES	Polyethersulfone
PDA	Polydopamine
PNIPAM	Poly(N-isopropylacrylamide
EDC	1-ethyl-3-(3-dimethylaminopropyl) carbodiimide
NHS	N-hydroxysuccinimide
DCS	Decellularized scaffold
PVA	Poly(vinyl alcohol)
LbL	Layer-by-layer
APTT	Activated partial thromboplastin time
PRT	Plasma recalcification time
PT	Prothrombin time
TT	Thrombin time
DHI	Dihydroxy-iron
BPSs	Bovine pericardial scaffolds
PU	Polyurethane
PCL	Poly(ε-caprolactone)
AEMA	2-aminoethyl methacrylate
PTFE	Poly-tetrafluoroethylene
ACT	Activated clotting time
PFO	Pericapsular fibrotic overgrowth
PA	Pullulan acetate
PEG	Polyethylene glycol
PLL	Poly-L-lysine
BSA	Bovine serum albumin
PEI	Poly(ethyleneimine)
MES	Morpholinoethane sulfonic acid
PLA	Polylactic acid
VEGF165	Vascular endothelial basic fibroblast growth factor
CH	Chitosan
Hep	Heparin
SDVG	Small-diameter vascular grafts
sNHS	N-hydroxysulfosuccinimide sodium salt
PSf	Polysulfone
PEC	Polyelectrolyte complex
PAN	Polyacrylonitrile
HAAb	Heparin-associated antiplatelet antibodies
AVG	Arteriovenous graft
PVDF	Poly-vinylidene fluoride
PAV	Polyallylamine
TA	Tannic acid
PEtOx	Poly(2-ethyl-2-oxazoline)
HUVEC	Human umbilical vein endothelial cells
Tyr	Tyrosinase
PMA	Phorbol 12-myristate 13-acetate
PMNLs	Polymorphonuclear leukocytes
DX	Dextran sulfate
DS	Dermatan sulfate
ES	Endothelial cell surface
HS	Heparan sulfate
AFNB	4-azido-lfluoro-2-nitrobenzene
SBS	Styrene-butadiene-styrene
CDI	Carbonyldiimidazole
SS	Stainless steel
ChS	Chondroitin 6-sulfate
TPE	Thermoplastic elastomer
EDAC	1-ethyl-3-(dimethyl-aminopropyl) carbodiimide hydrochloride
PE	Hydrophobic polyethylene
ECM	Extracellular matrix
SMC	Smooth muscle cells

Abbreviation	Meaning
HIT	Heparin-induced thrombocytopenia
PF4	Platelet factor 4
HD	Hemodialysis
C3	Complement component 3
HSA	Human serum albumin
FB	Fibrinogen
TRF	Transferrin
SH	Superhydrophobic
ZW	Zwitterionic
NO	Nitric oxide
ECC	Extracorporeal circuits
PVC	Polyvinyl chloride
KL	The Klotho Gene
SIS	Small intestinal submucosa
PES	Polyethersulfone
PDA	Polydopamine
PNIPAM	Poly(N-isopropylacrylamide
EDC	1-ethyl-3-(3-dimethylaminopropyl) carbodiimide
NHS	N-hydroxysuccinimide
DCS	Decellularized scaffold
PVA	Poly(vinyl alcohol)
LbL	Layer-by-layer
APTT	Activated partial thromboplastin time
PRT	Plasma recalcification time
PT	Prothrombin time
TT	Thrombin time
DHI	Dihydroxy-iron
BPSs	Bovine pericardial scaffolds
PU	Polyurethane
PCL	Poly(ε-caprolactone)
AEMA	2-aminoethyl methacrylate
PTFE	Poly-tetrafluoroethylene
ACT	Activated clotting time
PFO	Pericapsular fibrotic overgrowth
PA	Pullulan acetate
PEG	Polyethylene glycol
PLL	Poly-L-lysine
BSA	Bovine serum albumin
PEI	Poly(ethyleneimine)
MES	Morpholinoethane sulfonic acid
PLA	Polylactic acid
VEGF165	Vascular endothelial basic fibroblast growth factor
CH	Chitosan
Hep	Heparin
SDVG	Small-diameter vascular grafts
sNHS	N-hydroxysulfosuccinimide sodium salt
PSf	Polysulfone
PEC	Polyelectrolyte complex
PAN	Polyacrylonitrile
HAAb	Heparin-associated antiplatelet antibodies
AVG	Arteriovenous graft
PVDF	Poly-vinylidene fluoride
PAV	Polyallylamine
TA	Tannic acid
PEtOx	Poly(2-ethyl-2-oxazoline)
HUVEC	Human umbilical vein endothelial cells
Tyr	Tyrosinase
PMA	Phorbol 12-myristate 13-acetate
PMNLs	Polymorphonuclear leukocytes
DX	Dextran sulfate
DS	Dermatan sulfate
ES	Endothelial cell surface
HS	Heparan sulfate
AFNB	4-azido-lfluoro-2-nitrobenzene
SBS	Styrene-butadiene-styrene
CDI	Carbonyldiimidazole
SS	Stainless steel
ChS	Chondroitin 6-sulfate
TPE	Thermoplastic elastomer
EDAC	1-ethyl-3-(dimethyl-aminopropyl) carbodiimide hydrochloride
PE	Hydrophobic polyethylene
ECM	Extracellular matrix
SMC	Smooth muscle cells

References

1. Shen, J.I.; Winkelmayer, W.C. Use and safety of unfractionated heparin for anticoagulation during maintenance hemodialysis. Am. J. Kidney Dis. 2012, 60, 473–486. https://doi.org/10.1053/j.ajkd.2012.03.017.
2. Islam, M.S.; Hassan, Z.A.; Chalmin, F.; Vido, S.; Berrada, M.; Verhelst, D.; Donnadieu, P.; Moranne, O.; Esnault, V.L. Vitamin E-Coated and Heparin-Coated Dialyzer Membranes for Heparin-Free Hemodialysis: A Multicenter, Randomized, Crossover Trial. Am. J. Kidney Dis. 2016, 68, 752–762. https://doi.org/10.1053/j.ajkd.2016.05.013.
3. Harter, K.; Levine, M.; Henderson, S.O. Anticoagulation drug therapy: A review. West J. Emerg. Med. 2015, 16, 11–17. https://doi.org/10.5811/westjem.2014.12.22933.
4. van Rein, N.; Biedermann, J.S.; van der Meer, F.J.M.; Cannegieter, S.C.; Wiersma, N.; Vermaas, H.W.; Reitsma, P.H.; Kruip, M.; Lijfering, W.M. Major bleeding risks of different low-molecular-weight heparin agents: A cohort study in 12 934 patients treated for acute venous thrombosis. J. Thromb. Haemost. 2017, 15, 1386–1391. https://doi.org/10.1111/jth.13715.
5. Nelson-Piercy, C. Hazards of heparin: Allergy, heparin-induced thrombocytopenia and osteoporosis. Baillikres Clin. Obstet. Gynaecol. 1997, 11, 489–509.
6. Abdelrasoul, A.; Shoker, A. Induced Hemocompatibility of Polyethersulfone (PES) Hemodialysis Membrane using Polyvinylpyrrolidone: Investigation on Human Serum Fibrinogen Adsorption and Inflammatory Biomarkers Released. Eng. Res. Des. 2022, 177, 615–624.
7. Eduok, U.; Westphalen, H.; Abdelrasoul, A.; Shoker, A. Influence of UV‐irradiation intensity and exposure duration on the hemobiocompatibility enhancement of a novel synthesized phosphobetaine zwitterions polyethersulfone clinical hemodialysis membranes. Biomed. Mater. Res. Part B Appl. Biomater. 2022, 110, 573–586. https://doi.org/10.1002/jbm.b.34936.
8. Saadati, S.; Eduok, U.; Westphalen, H.; Abdelrasoul, A.; Shoker, A.; Choi, P.; Doan, H.; Ein-Mozaffari, F.; Zhu, N. In situ Synchrotron Imaging of Human Serum Proteins Interactions, Molecular Docking and Inflammatory Biomarkers of Hemocompatible Synthesized Zwitterionic Polymer Coated-Polyvinylidene Fluoride (PVDF) Dialysis Membranes. Interfaces 2021, 27, 101505.
9. Saadati, S.; Westphalen, H.; Eduok, U.; Abdelrasoul, A.; Shoker, A.; Choi, P.; Doan, H.; Ein-Mozaffari, F.; Zhu, N. Biocomptability Enhancement of Hemodialysis Membranes using Novel Zwitterionic: Experimental, in situ Synchrotron Imaging, Molecular Docking, and Clinical Inflammatory Biomarkers Investigations. Sci. Eng. C 2020, 117, 111301.
10. Westphalen, H.; Saadati, S.; Eduok, U.; Abdelrasoul, A.; Shoker, A.; Choi, P.; Doan, H.; Ein-Mozaffari, F. Case studies of clinical hemodialysis membranes: Influences of membrane morphology and biocompatibility on uremic blood-membrane interactions and inflammatory biomarkers. Rep. 2020, 10, 1–18.
11. Abdelrasoul, A.; Shoker, A. Influence of Hydration Shell of Hemodialysis Clinical Membranes on Surrogate Biomarkers Activation in Uremic Serum of Dialysis Patients. Eng. Adv. 2022, 4: 100049. https://doi.org/10.1016/j.bea.2022.100049.
12. Bolten, S.; Rinas, S.; Scheper, T. Heparin: role in protein purification and substitution with animal-component free material. Appl Microbiol Biotechnol. 2018; 102(20): 8647–8660.
13. Nguyen, T.H.; Xu, Y.; Brandt, S.; Mandelkow, M.; Raschke, R.; Strobel, U.; Delcea, M.; Zhou, W.; Liu, J.; Greinacher, A. Characterization of the interaction between platelet factor 4 and homogeneous synthetic low molecular weight heparins. J. Thromb Haemost 2020, 18, 390–398. https://doi.org/10.1111/jth.14657.
14. Abdelrasoul, A.; Westphalen, H.; Saadati, S.; Shoker, A. Hemodialysis biocompatibility mathematical models to predict the inflammatory biomarkers released in dialysis patients based on hemodialysis membrane characteristics and clinical practices. Rep. 2021, 11, 23080.
15. Ozkan, E.; Mondal, A.; Singha, P.; Douglass, M.; Hopkins, S.P.; Devine, R.; Garren, M.; Manuel, J.; Warnock, J.; Handa, H. Fabrication of Bacteria- and Blood-Repellent Superhydrophobic Polyurethane Sponge Materials. ACS Appl. Mater. Interfaces 2020, 12, 51160–51173. https://doi.org/10.1021/acsami.0c13098.
16. Cieplak, M.; Allan, D.B.; Leheny, R.L.; Reich, D.H. Proteins at air-water interfaces: A coarse-grained model. Langmuir 2014, 30, 12888–12896. https://doi.org/10.1021/la502465m.
17. Brancato, L.; Decrop, D.; Lammertyn, J.; Puers, R. Surface Nanostructuring of Parylene-C Coatings for Blood Contacting Implants. Materials 2018, 11, 1109. https://doi.org/10.3390/ma11071109.
18. Venault, A.; Wei, T.-C.; Shih, H.-L.; Yeh, C.-C.; Chinnathambi, A.; Alharbi, S.A.; Carretier, S.; Aimar, P.; Lai, J.-Y.; Chang, Y. Antifouling pseudo-zwitterionic poly(vinylidene fluoride) membranes with efficient mixed-charge surface grafting via glow dielectric barrier discharge plasma-induced copolymerization. Membr. Sci. 2016, 516, 13–25. https://doi.org/10.1016/j.memsci.2016.05.044.
19. Cai, N.; Li, Q.; Zhang, J.; Xu, T.; Zhao, W.; Yang, J.; Zhang, L. Antifouling zwitterionic hydrogel coating improves hemocompatibility of activated carbon hemoadsorbent. J. Colloid. Interface Sci. 2017, 503, 168–177. https://doi.org/10.1016/j.jcis.2017.04.024.
20. Mollahosseini, A.; Abdelrasoul, A.; Shoker, A. Latest advances in zwitterionic structures modified dialysis membranes. Today Chem. 2020, 15, 100227. https://doi.org/10.1016/j.mtchem.2019.100227.
21. Nazari, S.; Abdelrasoul, A. Surface Zwitterionization of HemodialysisMembranesfor Hemocompatibility Enhancement and Protein-mediated anti-adhesion: A Critical Review. Eng. Adv. 2022, 3, 100026.
22. Abdelrasoul, A.; Shoker, A. Investigations on the Impact of Hemodialysis Clinical Practices on Human Plasma Proteins Loss and von Willebrand factor. Kidney Int. Rep. 2022, 7, S258.
23. Venault, A.; Ye, C.C.; Lin, Y.C.; Tsai, C.W.; Jhong, J.F.; Ruaan, R.C.; Higuchi, A.; Chinnathambi, A.; Ho, H.T.; Chang, Y. Zwitterionic fibrous polypropylene assembled with amphiphatic carboxybetaine copolymers for hemocompatible blood filtration. Acta Biomater 2016, 40, 130–141. https://doi.org/10.1016/j.actbio.2016.01.031.
24. Schottler, S.; Becker, G.; Winzen, S.; Steinbach, T.; Mohr, K.; Landfester, K.; Mailander, V.; Wurm, F.R. Protein adsorption is required for stealth effect of poly(ethylene glycol)- and poly(phosphoester)-coated nanocarriers. Nat. Nanotechnol. 2016, 11, 372–377. https://doi.org/10.1038/nnano.2015.330.
25. Schottler, S.; Landfester, K.; Mailander, V. Controlling the Stealth Effect of Nanocarriers through Understanding the Protein Corona. Angew. Chem. Int. Ed. Engl. 2016, 55, 8806–8815. https://doi.org/10.1002/anie.201602233.
26. Tenzer, S.; Docter, D.; Kuharev, J.; Musyanovych, A.; Fetz, V.; Hecht, R.; Schlenk, F.; Fischer, D.; Kiouptsi, K.; Reinhardt, C.; et al. Rapid formation of plasma protein corona critically affects nanoparticle pathophysiology. Nat. Nanotechnol. 2013, 8, 772–781. https://doi.org/10.1038/nnano.2013.181.
27. Deng, Z.J.; Liang, M.; Monteiro, M.; Toth, I.; Minchin, R.F. Nanoparticle-induced unfolding of fibrinogen promotes Mac-1 receptor activation and inflammation. Nat. Nanotechnol. 2011, 6, 39–44. https://doi.org/10.1038/nnano.2010.250.
28. Szleifer, F.F.a.I. Kinetics and Thermodynamics of Protein Adsorption: A Generalized Molecular Theoretical Approach. J. 2001, 80, 2568–2589.
29. Sivaraman, B.; Latour, R.A. Time-dependent conformational changes in adsorbed albumin and its effect on platelet adhesion. Langmuir 2012, 28, 2745–2752. https://doi.org/10.1021/la204777x.
30. Kristyn, S.; Bohl, J.L.W. Nitric oxide-generating polymers reduce platelet adhesion and smooth muscle cell proliferation. Biomaterials 2000, 21, 2273–
31. Tousoulis, D.; Kampoli, A.M.; Tentolouris Nikolaos Papageorgiou, C.; Stefanadis, C. The Role of Nitric Oxide on Endothelial Function. Vasc. Pharmacol. 2012, 10, 4–18.
32. Handa, H.; Brisbois, E.J.; Major, T.C.; Refahiyat, L.; Amoako, K.A.; Annich, G.M.; Bartlett, R.H.; Meyerhoff, M.E. In vitro and in vivo study of sustained nitric oxide release coating using diazeniumdiolate-oped poly(vinyl chloride) matrix with poly(lactide-co-glycolide) additive. J. Mater. Chem. B 2013, 1, 3578–3587. https://doi.org/10.1039/C3TB20277A.
33. Grossi, L.; Montevecchi, P.C. A Kinetic Study of S-Nitrosothiol Decomposition. Eur. 2002, 8, 380–387. https://doi.org/10.1002/1521-3765(20020118)8:2<380::AID-CHEM380>3.0.CO;2-P.
34. Frost, M.C.; Meyerhoff, M.E. Controlled Photoinitiated Release of Nitric Oxide from Polymer Films Containing S-Nitroso-N-acetyl-DL-penicillamine Derivatized Fumed Silica Filler. Am. Chem. Soc. 2004, 126, 1348–1349. https://doi.org/10.1021/ja039466i.
35. Broniowska, K.A.; Hogg, N. The chemical biology of S-nitrosothiols. Antioxid. Redox Signal 2012, 17, 969–980. https://doi.org/10.1089/ars.2012.4590.
36. Roberts, T.R.; Neufeld, M.J.; Meledeo, M.A.; Cap, A.P.; Cancio, L.C.; Reynolds, M.M.; Batchinsky, A.I. A metal organic framework reduces thrombus formation and platelet aggregation ex vivo. J. Trauma Acute Care Surg. 2018, 85, 572–579. https://doi.org/10.1097/TA.0000000000001982.
37. Wo, Y.; Brisbois, E.J.; Wu, J.; Li, Z.; Major, T.C.; Mohammed, A.; Wang, X.; Colletta, A.; Bull, J.L.; Matzger, A.J.; et al. Reduction of Thrombosis and Bacterial Infection via Controlled Nitric Oxide (NO) Release from S-Nitroso-N-acetylpenicillamine (SNAP) Impregnated CarboSil Intravascular Catheters. ACS Biomater. Sci. Eng. 2017, 3, 349–359. https://doi.org/10.1021/acsbiomaterials.6b00622.
38. Douglass, M.E.; Goudie, M.J.; Pant, J.; Singha, P.; Hopkins, S.; Devine, R.; Schmiedt, C.W.; Handa, H. Catalyzed Nitric Oxide Release Via Cu Nanoparticles Leads to an Increase in Antimicrobial Effects and Hemocompatibility for Short Term Extracorporeal Circulation. ACS Appl. Bio. Mater. 2019, 2, 2539–2548. https://doi.org/10.1021/acsabm.9b00237.
39. Vaithilingam, V.; Kollarikova, G.; Qi, M.; Larsson, R.; Lacik, I.; Formo, K.; Marchese, E.; Oberholzer, J.; Guillemin, G.J.; Tuch, B.E. Beneficial effects of coating alginate microcapsules with macromolecular heparin conjugates-in vitro and in vivo study. Tissue Eng. Part A 2014, 20, 324–334. https://doi.org/10.1089/ten.TEA.2013.0254.
40. Bünger, C.M.; Gerlach, C.; Freier, T.; Schmitz, K.P.; Pilz, M.; Werner, C.; Jonas, L.; Schareck, W.; Hopt, U.T.; De Vos, P. Biocompatibility and surface structure of chemically modified immunoisolating alginate–PLL capsules. 2003, 67, 1219–1227.
41. Chan, H.-M.; Erathodiyil, N.; Wu, H.; Lu, H.; Zheng, Y.; Ying, J.Y. Calcium cross-linked zwitterionic hydrogels as antifouling materials. Today Commun. 2020, 23, 100950. https://doi.org/10.1016/j.mtcomm.2020.100950.
42. Tsai, C.C.; Chang, Y.; Sung, H.W.; Hsu, J.C.; Chen, C.N. Effects of heparin immobilization on the surface characteristics of a biological tissue fixed with a naturally occurring crosslinking agent (genipin): An in vitro study. Biomaterials 2001, 22, 523–533.
43. Zhu, A.; Zhang, M.; Wu, J.; Shen, J. Covalent immobilization of chitosan/heparin complex with a photosensitive hetero-bifunctional crosslinking reagent on PLA surface. Biomaterials 2002, 23, 4657–4665.
44. Wang, J.; Chen, Y.; Liu, T.; Wang, X.; Liu, Y.; Wang, Y.; Chen, J.; Huang, N. Covalent co-immobilization of heparin/laminin complex that with different concentration ratio on titanium surface for selectively direction of platelets and vascular cells behavior. Surf. Sci. 2014, 317, 776–786. https://doi.org/10.1016/j.apsusc.2014.07.129.
45. Chen, Q.; He, Y.; Zhao, Y.; Chen, L. Intervening oxidative stress integrated with an excellent biocompatibility of hemodialysis membrane fabricated by nucleobase-recognized co-immobilization strategy of tannic acid, looped PEtOx brush and heparin. Membr. Sci. 2021, 625, 119174. https://doi.org/10.1016/j.memsci.2021.119174.
46. Yang, J.M.; Wang, M.C.; Hsu, Y.G.; Chang, C.H.; Lo, S.K. Preparation of heparin containing SBS-g-VP copolymer membrane for biomaterial usage. Membr. Sci. 1998, 138, 19–27.
47. Zhang, X.; Zhang, G.; Zhang, H.; Li, J.; Yao, X.; Tang, B. Surface immobilization of heparin and chitosan on titanium to improve hemocompatibility and antibacterial activities. Coll. Surf. B Biointerfaces 2018, 172, 338–345. https://doi.org/10.1016/j.colsurfb.2018.08.060.
48. Liu, T.; Liu, Y.; Chen, Y.; Liu, S.; Maitz, M.F.; Wang, X.; Zhang, K.; Wang, J.; Wang, Y.; Chen, J.; et al. Immobilization of heparin/poly-(L)-lysine nanoparticles on dopamine-coated surface to create a heparin density gradient for selective direction of platelet and vascular cells behavior. Acta Biomater. 2014, 10, 1940–1954. https://doi.org/10.1016/j.actbio.2013.12.013.
49. Drozd, N.N.; Lunkov, A.P.; Shagdarova, B.T.; Zhuikova, Y.V.; Il'ina, A.V.; Varlamov, V.P. Chitosan/heparin layer-by-layer coatings for improving thromboresistance of polyurethane. Interfaces 2022, 28, 101674. https://doi.org/10.1016/j.surfin.2021.101674.
50. Vaithilingam, V.; Steinkjer, B.; Ryan, L.; Larsson, R.; Tuch, B.E.; Oberholzer, J.; Rokstad, A.M. In Vitro and In Vivo Biocompatibility Evaluation of Polyallylamine and Macromolecular Heparin Conjugates Modified Alginate Microbeads. Sci. Rep. 2017, 7, 1– https://doi.org/10.1038/s41598-017-11989-1.
51. Manabe, K.; Nara, H. Construction of stable biological albumin/heparin multilayers for elastic coatings on hydrophobic antithrombogenic artificial blood vessels. Int. 2021, 156, 106843. https://doi.org/10.1016/j.triboint.2020.106843.
52. Große-Berkenbusch, K.; Avci-Adali, M.; Arnold, M.; Cahalan, L.; Cahalan, P.; Velic, A.; Maček, B.; Schlensak, C.; Wendel, H.-P.; Stoppelkamp, S. Profiling of time-dependent human plasma protein adsorption on non-coated and heparin-coated oxygenator membranes. Adv. 2022, 156, 106843. https://doi.org/10.1016/j.bioadv.2022.213014.
53. Zhao, P.; Fang, Q.; Gao, D.; Wang, Q.; Cheng, Y.; Ao, Q.; Wang, X.; Tian, X.; Zhang, Y.; Tong, H.; et al. Klotho functionalization on vascular graft for improved patency and endothelialization. Sci. Eng. C Mater. Biol. Appl. 2022, 133, 112630. https://doi.org/10.1016/j.msec.2021.112630.
54. Rose, I.I.; Kather, M.; Roth, H.; Dünkelberg, H.; Rein, L.; Klimosch, S.N.; Schmolz, M.; Wessling, M. Single-step chitosan functionalized membranes for heparinization. Membr. Sci. 2022, 655, 120567. https://doi.org/10.1016/j.memsci.2022.120567.
55. Rose, I.I.; Roth, H.; Xie, J.; Hollmann, F.; Votteler, S.; Storr, M.; Krause, B.; Wessling, M. Chemistry in a spinneret—Polydopamine functionalized hollow fiber membranes. Membr. Sci. 2022, 648, 120324. https://doi.org/10.1016/j.memsci.2022.120324.
56. Lu, Y.T.; Zeng, K.; Fuhrmann, B.; Woelk, C.; Zhang, K.; Groth, T. Engineering of Stable Cross-Linked Multilayers Based on Thermo-Responsive PNIPAM-Grafted-Chitosan/Heparin to Tailor Their Physiochemical Properties and Biocompatibility. ACS Appl. Mater. Interfaces 2022, 14, 29550–29562. https://doi.org/10.1021/acsami.2c05297.
57. Sun, G.; Li, Y.; Liu, C.; Jiang, X.; Yang, L.; He, L.; Song, S.; Zhang, J.; Shen, J.; Qiao, T. Chitosan-Heparin Polyelectrolyte Multilayer-Modified Poly(vinyl alcohol) Vascular Patches based on a Decellularized Scaffold for Vascular Regeneration. ACS Appl. Bio. Mater. 2022, 5, 2928–2934. https://doi.org/10.1021/acsabm.2c00266.
58. Nguyen, M.T.N.; Tran, H.L.B. Heparinization of the bovine pericardial scaffold by layer-by-layer (LBL) assembly technique. Journal of Science: Mater. Devices 2022, 7, 100405. https://doi.org/10.1016/j.jsamd.2021.11.007.
59. Dehghani, F.; Khorasani, M.T.Movahedi, M. Fabrication of polyurethane—Heparinized carbon nanotubes composite for heart valves application. Chem. Phys. 2022, 280, 125819. https://doi.org/10.1016/j.matchemphys.2022.125819.
60. Kim, S.E.; Jeong, S.I.; Shim, K.M.; Jang, K.; Park, J.S.; Lim, Y.M.; Kang, S.S. In Vivo Evaluation of Gamma-Irradiated and Heparin-Immobilized Small-Diameter Polycaprolactone Vascular Grafts with VEGF in Aged Rats. Polymers 2022, 14, 1265. https://doi.org/10.3390/polym14061265.
61. Zea, N.; Menard, G.; Le, L.; Bazan, H.; Sternbergh, W.C.; Smith, T. 48. Heparin Bonded PTFE Does Not Improve Hemodialysis Arteriovenous Graft Function. Vasc. Surg. 2015, 29, 645. https://doi.org/10.1016/j.avsg.2015.04.049.
62. Borawski, J.; Naumnik, B.; Mysliwiec, M. Activation of hepatocyte growth factor/activin A/follistatin system during hemodialysis: Role of heparin. Kidney Int. 2003, 64, 2229–2237. https://doi.org/10.1046/j.1523-1755.2003.00307.x.
63. Baird, C.W.; Zurakowski, D.; Robinson, B.; Gandhi, S.; Burdis-Koch, L.; Tamblyn, J.; Munoz, R.; Fortich, K.; Pigula, F.A. Anticoagulation and pediatric extracorporeal membrane oxygenation: Impact of activated clotting time and heparin dose on survival. Ann. Thorac. Surg. 2007, 83, 912–919; discussion 919-20. https://doi.org/10.1016/j.athoracsur.2006.09.054.
64. Luley, C.; Westphal, S.; Ambrosch, A.; Neumann, K.H. Anticoagulation with heparin during hemodialysis causes pronounced LDL alterations. In Proceedings of the 11th International Symposium on Atherosclerosis, Paris, France, 5–9 October 1997.
65. Sung, W.J.; Na, K.; Bae, Y.H. Biocompatibility and interference eliminating property of pullulan acetate/polyethylene glycol/heparin membrane for the outer layer of an amperometric glucose sensor. Actuators B Chem. 2004, 99, 393–398. https://doi.org/10.1016/j.snb.2003.12.005.
66. Dumont, G. C0281 Heparin-induced thrombocytopenia (HIT) type 2 caused by preventive anticoagulation of the circuit of hemodialysis (HD): A case report. Res. 2012, 130, S185. https://doi.org/10.1016/j.thromres.2012.08.220.
67. Glick, D.; Dzierba, A.L.; Abrams, D.; Muir, J.; Eisenberger, A.; Diuguid, D.; Abel, E.; Agerstrand, C.; Bacchetta, M.; Brodie, D. Clinically suspected heparin-induced thrombocytopenia during extracorporeal membrane oxygenation. J. Crit. Care 2015, 30, 1190–1194. https://doi.org/10.1016/j.jcrc.2015.07.030.
68. Pham, P.T.; Miller, J.M.; Demetrion, G.; Lew, S.Q. Clotting by Heparin of Hemoaccess for Hemodialysis in an End-Stage Renal Disease Patient. J. Kidney Dis. 1995, 25, 642–647.
69. Warkentin, T.E. Hemodialysis-associated acute systemic reactions and heparin-induced thrombocytopenia. Thromb. Res. 2012, 129, 405–406. https://doi.org/10.1016/j.thromres.2011.11.004.
70. Doi, Y.; Koga, K.; Sugioka, S.; Inoue, Y.; Arisato, T.; Nishioka, K.; Ishihara, T.; Sugawara, A. Heparin-induced thrombocytopenia among incident hemodialysis patients anticoagulated with low molecular weight heparin: A single-center retrospective study. Nefrologia 2021, 41, 356–358. https://doi.org/10.1016/j.nefro.2020.05.012.
71. Welp, H.; Ellger, B.; Scherer, M.; Lanckohr, C.; Martens, S.; Gottschalk, A. Heparin-induced thrombocytopenia during extracorporeal membrane oxygenation. J. Cardiothorac. Vasc. Anesth. 2014, 28, 342–344. https://doi.org/10.1053/j.jvca.2012.10.014.
72. Yamamoto, S.; Koide, M.; Matsuo, M.; Suzuki, S.; Ohtaka, M.; Saika, S.; Matsuo, T. Heparin-Induced Thrombocytopenia in Hemodialysis Patients. J. Kidney Dis. 1996, 28, 82–85.
73. Carrier, M.; Rodger, M.A.; Fergusson, D.; Doucette, S.; Kovacs, M.J.; Moore, J.; Kelton, J.G.; Knoll, G.A. Increased mortality in hemodialysis patients having specific antibodies to the platelet factor 4-heparin complex. Kidney Int. 2008, 73, 213–219. https://doi.org/10.1038/sj.ki.5002631.
74. Tanhehco, Y.C.; Cuker, A.; Rudnick, M.; Sachais, B.S. Investigation of a potential protective mechanism against heparin-induced thrombocytopenia in patients on chronic intermittent hemodialysis. Thromb. Res. 2013, 131, 244–248. https://doi.org/10.1016/j.thromres.2012.12.010.
75. Andrianova, I.; Hayes, V.M.; Madeeva, D.; Litvinov, R.I.; Cines, D.B.; Poncz, M.; Weisel, J.W.; Rauova, L. Membrane Remodeling By Pathogenic Antibodies Underlies Monocyte Activation in Heparin-Induced Thrombocytopenia. Blood 2015, 126, 2244–2244. https://doi.org/10.1182/blood.V126.23.2244.2244.
76. Matsuo, T.; Nakao, K.; Yamada, T.; Matsuo, O. A new thrombin inhibitor MD805 and thrombocytopenia encountered with heparin hemodialysis. Res. 1986, 44, 247–251.
77. Prechel, M.M.; Jeske, W.P.; Walenga, J.M. Physiological changes in membrane-expressed platelet factor 4: Implications in heparin-induced thrombocytopenia. Thromb. Res. 2010, 125, e143–e14 https://doi.org/10.1016/j.thromres.2009.10.021.
78. Ahmed, M.S.; Amin, T.; Amin, A.; Nashawi, M.; Haloot, J.; Fichardt, H.; Prasad, A.; Almomani, A. Valve-in-Valve Transcatheter Aortic-Valve Replacement with Basilica in a Patient with History of Evans Syndrome, Heparin Induced Thrombocytopenia and Hemodialysis. Is It Even Possible? Am. Coll. Cardiol. 2021, 77, 2357. https://doi.org/10.1016/s0735-1097(21)03712-8.
79. Ichinose, K.; Okamoto, T.; Tanimoto, H.; Yoshitake, A.; Tashiro, M.; Sakanashi, Y.; Kuwana, K.; Tahara, K.; Kamiya, M.; Terasaki, H. Comparison of a New Heparin-coated Dense Membrane Lung with Nonheparin-coated Dense Membrane Lung for Prolonged Extracorporeal Lung Assist in Goats. Organs 2004, 28, 993–1001.
80. Pekna, M.; Hagman, L.; Halden, E.; Nilsson, U.R.; Nilsson, B.; Thelin, S. Complement Activation During Cardiopulmonary Bypass: Effects of Immobilized Heparin. Ann. Thorac. Surg. 1994, 58, 421–424.
81. Ding, Y.; Yang, M.; Yang, Z.; Luo, R.; Lu, X.; Huang, N.; Huang, P.; Leng, Y. Cooperative control of blood compatibility and re-endothelialization by immobilized heparin and substrate topography. Acta Biomater. 2015, 15, 150–163. https://doi.org/10.1016/j.actbio.2014.12.014.
82. Naumnik, B.; Pawlak, K.; Mysliwiec, M. Different effect of unfractionated heparin and enoxaparin on circulating proangiogenic factors during hemodialysis: A cross-over study. Cytokine 2007, 40, 98–104. https://doi.org/10.1016/j.cyto.2007.08.011.
83. Kara, F.; Aksoy, E.A.; Yuksekdag, Z.; Aksoy, S.; Hasirci, N. Enhancement of antibacterial properties of polyurethanes by chitosan and heparin immobilization. Surf. Sci. 2015, 357, 1692–1702. https://doi.org/10.1016/j.apsusc.2015.09.227.
84. Perrenoud, I.A.; Rangel, E.C.; Mota, R.P.; Durrant, S.F.; Cruz, N.C.D. Evaluation of Blood Compatibility of Plasma Deposited Heparin-like Films and SF6 Plasma Treated Surfaces. Res. 2010, 13, 95–98.
85. Caracciolo, P.C.; Diaz-Rodriguez, P.; Ardao, I.; Moreira, D.; Montini-Ballarin, F.; Abraham, G.A.; Concheiro, A.; Alvarez-Lorenzo, C. Evaluation of human umbilical vein endothelial cells growth onto heparin-modified electrospun vascular grafts. Int. J. Biol. Macromol. 2021, 179, 567–575. https://doi.org/10.1016/j.ijbiomac.2021.03.008.
86. Tseng, P.Y.; Rele, S.M.; Sun, X.L.; Chaikof, E.L. Fabrication and characterization of heparin functionalized membrane-mimetic assemblies. Biomaterials 2006, 27, 2627–2636. https://doi.org/10.1016/j.biomaterials.2005.10.032.
87. Wang, L.; Fang, F.; Liu, Y.; Li, J.; Huang, X. Facile preparation of heparinized polysulfone membrane assisted by polydopamine/polyethyleneimine co-deposition for simultaneous LDL selectivity and biocompatibility. Surf. Sci. 2016, 385, 308–317. https://doi.org/10.1016/j.apsusc.2016.05.134.
88. Kastellorizios, M.; Michanetzis, G.P.; Pistillo, B.R.; Mourtas, S.; Klepetsanis, P.; Favia, P.; Sardella, E.; d'Agostino, R.; Missirlis, Y.F.; Antimisiaris, S.G. Haemocompatibility improvement of metallic surfaces by covalent immobilization of heparin-liposomes. Int. J. Pharm. 2012, 432, 91–98. https://doi.org/10.1016/j.ijpharm.2012.04.057.
89. Norbert Weber, H.P.W. Gerhard Ziemer Hemocompatibility of heparin-coated surfaces and the role of selective plasma protein adsorption. Biomaterials 2002, 23, 429-439.
90. Lin, W.C.; Liu, T.Y.; Yang, M.C. Hemocompatibility of polyacrylonitrile dialysis membrane immobilized with chitosan and heparin conjugate. Biomaterials 2004, 25, 1947–1957. https://doi.org/10.1016/j.biomaterials.2003.08.027.
91. Jacob Kaleekkal, N. Heparin immobilized graphene oxide in polyetherimide membranes for hemodialysis with enhanced hemocompatibility and removal of uremic toxins. Membr. Sci. 2021, 623, 119068. https://doi.org/10.1016/j.memsci.2021.119068.
92. Humphries, J.E.; Kaplan, D.M.; Bolton, W.K. Heparin Skin Necrosis: Delayed Occurrence in a Patient on Hemodialysis. J. Kidney Dis. 1991, 17, 233–236. https://doi.org/10.1016/s0272-6386(12)81135-8.
93. Mureebe, L.; Coats, R.D.; Silliman, W.R. Heparin-associated antiplatelet antibodies increase morbidity and mortality in hemodialysis patients. Vasc. Surg. 2005, 41, 560. https://doi.org/10.1016/j.jvs.2004.12.019.
94. Zea, N.; Menard, G.; Le, L.; Luo, Q.; Bazan, H.A.; Sternbergh, W.C., 3rd; Smith, T.A. Heparin-Bonded Polytetrafluorethylene Does Not Improve Hemodialysis Arteriovenous Graft Function. Ann. Vasc. Surg. 2016, 30, 28–33. https://doi.org/10.1016/j.avsg.2015.06.071.
95. Evenepoel, P.; Dejagere, T.; Verhamme, P.; Claes, K.; Kuypers, D.; Bammens, B.; Vanrenterghem, Y. Heparin-coated polyacrylonitrile membrane versus regional citrate anticoagulation: A prospective randomized study of 2 anticoagulation strategies in patients at risk of bleeding. Am. J. Kidney Dis. 2007, 49, 642–649. https://doi.org/10.1053/j.ajkd.2007.02.001.
96. Yu, X.; Zhu, Y.; Zhang, T.; Deng, L.; Li, P.; Wang, X.; Hsiao, B.S. Heparinized thin-film composite membranes with sub-micron ridge structure for efficient hemodialysis. Membr. Sci. 2020, 599, 117706. https://doi.org/10.1016/j.memsci.2019.117706.
97. Lin, D.-J.; Lin, D.-T.; Young, T.-H.; Huang, F.-M.; Chen, C.-C.; Cheng, L.-P. Immobilization of heparin on PVDF membranes with microporous structures. Membr. Sci. 2004, 245, 137–146. https://doi.org/10.1016/j.memsci.2004.07.028.
98. Guo, J.; Li, K.; Ning, C.; Liu, X. Improved cellular bioactivity by heparin immobilization on polycarbonate film via an aminolysis modification for potential tendon repair. Int. J. Biol. Macromol. 2020, 142, 835–845. https://doi.org/10.1016/j.ijbiomac.2019.09.136.
99. Begovac, P.C.; Thomson, R.C.; Fisher, J.L.; Hughson, A.; Gallhagen, A. Improvements in GORE-TEX vascular graft performance by Carmeda BioActive surface heparin immobilization. Eur. J. Vasc. Endovasc. Surg. 2003, 25, 432–437. https://doi.org/10.1053/ejvs.2002.1909.
100. Zhao, J.; Chen, Y.; Yang, S.; Wu, S.; Zeng, R.; Wu, H.; Zhang, J.; Zha, Z.; Tu, M. Improving blood-compatibility via surface heparin-immobilization based on a liquid crystalline matrix. Sci. Eng. C Mater. Biol. Appl. 2016, 58, 133–141. https://doi.org/10.1016/j.msec.2015.08.025.
101. Kopp, R.; Mottaghy, K.; Kirschfink, M. Mechanism of Complement Activation During Extracorporeal Blood-Biomaterial Interaction: Effects of Heparin Coated and Uncoated Surfaces. Asaio J. 2002, 48, 598–605. https://doi.org/10.1097/01.MAT.0000033639.23941.7E.
102. Tran, D.L.; Le Thi, P.; Lee, S.M.; Hoang Thi, T.T.; Park, K.D. Multifunctional surfaces through synergistic effects of heparin and nitric oxide release for a highly efficient treatment of blood-contacting devices. J. Release 2021, 329, 401–412. https://doi.org/10.1016/j.jconrel.2020.12.009.
103. Sela, S.; Shurtz-Swirski, R.; Shapiro, G.; Nasser, L.; Hamzi, M.; Shasha, S.M.; Kristal, B. Oxidative stress during hemodialysis: Effect of heparin. Kidney Int. Suppl. 2001, 78, S159–S163. https://doi.org/10.1046/j.1523-1755.2001.59780159.x.
104. Erdtmann, M.; Keller, R.; Baumann, H. Photochemical immobilization of heparin, dermatan sulphate, dextran sulphate and endothelial cell surface heparan sulphate onto cellulose membranes for the preparation of athrombogenic and antithrombogenic polymers. Biomaterials 1994, 15, 1043–1048.
105. Seifert, B.; Mihanetzis, G.; Groth, T.; Albrecht, W.; Richau, K.; Missirlis, Y.; Paul, D.; Von Sengbusch, G. Polyetherimide: A New Membrane-Forming Polymer for Biomedical Applications. Organs 2002, 26, 189–199.
106. Gao, A.; Liu, F.; Xue, L. Preparation and evaluation of heparin-immobilized poly (lactic acid) (PLA) membrane for hemodialysis. Membr. Sci. 2014, 452, 390–399. https://doi.org/10.1016/j.memsci.2013.10.016.
107. Badr, I.H.; Gouda, M.; Abdel-Sattar, R.; Sayour, H.E. Reduction of thrombogenicity of PVC-based sodium selective membrane electrodes using heparin-modified chitosan. Carbohydr. Polym. 2014, 99, 783–790. https://doi.org/10.1016/j.carbpol.2013.08.087.
108. Laville, M.; Dorval, M.; Fort Ros, J.; Fay, R.; Cridlig, J.; Nortier, J.L.; Juillard, L.; Debska-Slizien, A.; Fernandez Lorente, L.; Thibaudin, D.; et al. Results of the HepZero study comparing heparin-grafted membrane and standard care show that heparin-grafted dialyzer is safe and easy to use for heparin-free dialysis. Kidney Int. 2014, 86, 1260–1267. https://doi.org/10.1038/ki.2014.225.
109. Huang, L.Y.; Yang, M.C. Surface immobilization of chondroitin 6-sulfate/heparin multilayer on stainless steel for developing drug-eluting coronary stents. Colloids. Surf. B Biointerfaces 2008, 61, 43–52. https://doi.org/10.1016/j.colsurfb.2007.07.004.
110. Wu, Y.-B.; Li, K.; Xiang, D.; Zhang, M.; Yang, D.; Zhang, J.-H.; Mao, J.; Wang, H.; Guo, W.-L. Surface immobilization of heparin on functional polyisobutylene-based thermoplastic elastomer as a potential artificial vascular graft. Surf. Sci. 2018, 445, 8–15. https://doi.org/10.1016/j.apsusc.2018.03.048.
111. Jiang, J.-H.; Zhu, L.-P.; Li, X.-L.; Xu, Y.-Y.; Zhu, B.-K. Surface modification of PE porous membranes based on the strong adhesion of polydopamine and covalent immobilization of heparin. Membr. Sci. 2010, 364, 194–202. https://doi.org/10.1016/j.memsci.2010.08.017.
112. Yu, C.; Yang, H.; Wang, L.; Thomson, J.A.; Turng, L.S.; Guan, G. Surface modification of polytetrafluoroethylene (PTFE) with a heparin-immobilized extracellular matrix (ECM) coating for small-diameter vascular grafts applications. Sci. Eng. C Mater. Biol. Appl. 2021, 128, 112301. https://doi.org/10.1016/j.msec.2021.11230.